InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $15.620 1.76 (10.13%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,307 App 4D and Report for Half-Year Ended 30 June 2021 19 Aug 2021 8:07AM $6.500 $15.620 risen by 140.31%
$5,307 GenesisCare Collaboration Expands Prostate Cancer Activity 19 Aug 2021 8:07AM $6.500 $15.620 risen by 140.31%
$5,307 Telix and Merck pan-cancer clinical collaboration 18 Aug 2021 9:26AM $6.090 $15.620 risen by 156.49%
$5,307 Two studies explore TLX assets in Breast Cancer Theranostics 18 Aug 2021 8:54AM $6.090 $15.620 risen by 156.49%
$5,307 TLX66 in Phase II Academic Study of Pediatric Leukemia 17 Aug 2021 8:19AM $6.300 $15.620 risen by 147.94%
$5,307 Telix H1 2021 Results and Company Update Conference Call 11 Aug 2021 8:18AM $5.530 $15.620 risen by 182.46%
$5,307 1st Patient Dosed in CUPID study of TLX592 5 Aug 2021 8:23AM $5.300 $15.620 risen by 194.72%
$5,307 Telix Seneffe Production Facility - Progress Update 30 Jul 2021 8:14AM $5.340 $15.620 risen by 192.51%
$5,307 App 4C and Activities Report for June 2021 Quarter 22 Jul 2021 8:18AM $5.200 $15.620 risen by 200.38%
$5,307 Notification of cessation of securities - TLX 22 Jul 2021 8:16AM $5.200 $15.620 risen by 200.38%
$5,307 Notification of cessation of securities - TLX 22 Jul 2021 8:16AM $5.200 $15.620 risen by 200.38%
$5,307 Notification of cessation of securities - TLX 22 Jul 2021 8:15AM $5.200 $15.620 risen by 200.38%
$5,307 Notification of cessation of securities - TLX 22 Jul 2021 8:15AM $5.200 $15.620 risen by 200.38%
$5,307 Notification of cessation of securities - TLX 22 Jul 2021 8:15AM $5.200 $15.620 risen by 200.38%
$5,307 Notification regarding unquoted securities - TLX 22 Jul 2021 8:15AM $5.200 $15.620 risen by 200.38%
$5,307 Notification regarding unquoted securities - TLX 22 Jul 2021 8:15AM $5.200 $15.620 risen by 200.38%
$5,307 ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update 20 Jul 2021 8:19AM $5.070 $15.620 risen by 208.09%
$5,307 Ky Williamson to lead corporate communications and IR 12 Jul 2021 8:29AM $5.550 $15.620 risen by 181.44%
$5,307 Change in substantial holding 5 Jul 2021 7:25PM $5.730 $15.620 risen by 172.60%
$5,307 Application for quotation of securities - TLX 2 Jul 2021 8:27AM $5.910 $15.620 risen by 164.30%
$5,307 Cleansing Notice - issue of shares upon exercise of options 2 Jul 2021 8:26AM $5.910 $15.620 risen by 164.30%
$5,307 1st patient dosed in TLX250-CDx study in Bladder Cancer 23 Jun 2021 9:03AM $5.630 $15.620 risen by 177.44%
$5,307 TLX101 for Glioblastoma Therapy - Clinical Trial Update 21 Jun 2021 8:23AM $6.410 $15.620 risen by 143.68%
$5,307 Update on FDA New Drug Application Review for Illuccix 17 Jun 2021 8:20AM $5.620 $15.620 risen by 177.94%
$5,307 Telix and ATS $1.56M Eurostars Grant for Alpha Therapy 7 Jun 2021 8:25AM $4.670 $15.620 risen by 234.48%

601 - 625 of 951 results

Page 25 of 39

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.